EBGI Category: IBD
-
Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial
American College of Gastroenterology / EBGI Articles / IBD / Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled TrialTofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial Ellen Axenfeld, MD1 and Elie S. Al Kazzi, MD,…
-
The Edge of a New Frontier: Anti-TL1A Monoclonal Antibodies for Ulcerative Colitis
American College of Gastroenterology / EBGI Articles / IBD / The Edge of a New Frontier: Anti-TL1A Monoclonal Antibodies for Ulcerative ColitisThe Edge of a New Frontier: Anti-TL1A Monoclonal Antibodies for Ulcerative Colitis Maryam Ibrahim, MD1 and Bharati Kochar, MD, MS2…
-
Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience… with Potential for Improved Efficacy?
American College of Gastroenterology / EBGI Articles / IBD / Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience… with Potential for Improved Efficacy?Subcutaneous Infliximab for Maintenance of IBD Remission: Added Convenience With Potential for Improved Efficacy? Elie S. Al Kazzi, MD, MPH…
-
Risankizumab is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm
American College of Gastroenterology / EBGI Articles / IBD / Risankizumab is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment ParadigmRisankizumab Is Superior to Placebo for Induction and Maintenance of Moderate-Severe Ulcerative Colitis (UC): Assessing the UC Treatment Paradigm Rahul…
-
Risankizumab is Superior to Ustekinumab for Induction and Maintenance of Crohn’s disease: The SEQUENCE Trial
American College of Gastroenterology / EBGI Articles / IBD / Risankizumab is Superior to Ustekinumab for Induction and Maintenance of Crohn’s disease: The SEQUENCE TrialRisankizumab Is Superior to Ustekinumab for Induction and Maintenance of Crohn’s Disease: The SEQUENCE Trial Sara Ghoneim, MD1 and Bharati…
-
Long-Term Efficacy and Safety of Ustekinumab for Ulcerative Colitis: 4-Year Data from the UNIFI Maintenance Study
American College of Gastroenterology / EBGI Articles / IBD / Long-Term Efficacy and Safety of Ustekinumab for Ulcerative Colitis: 4-Year Data from the UNIFI Maintenance StudyLong-Term Efficacy and Safety of Ustekinumab for Ulcerative Colitis: 4-Year Data from the UNIFI Long-Term Maintenance Study Rahul Dalal, MD,…
-
PROFILE: Can Molecular Biomarkers Predict Outcomes to Crohn’s Disease Treatment?
American College of Gastroenterology / EBGI Articles / IBD / PROFILE: Can Molecular Biomarkers Predict Outcomes to Crohn’s Disease Treatment?PROFILE: Can Molecular Biomarkers Predict Outcomes to Crohn’s Disease Treatment? Bharati Kochar, MD, MS Assistant Professor of Medicine, Division of…
-
Ustekinumab and Vedolizumab Demonstrate Safety During Pregnancy: Updates from the PIANO Registry
American College of Gastroenterology / EBGI Articles / IBD / Ustekinumab and Vedolizumab Demonstrate Safety During Pregnancy: Updates from the PIANO RegistryUstekinumab and Vedolizumab Demonstrate Safety During Pregnancy-Updates From the PIANO Registry Rahul Dalal, MD, MPH Instructor, Division of Gastroenterology, Hepatology,…
-
Mirikizumab Is Effective for Induction and Maintenance of Ulcerative Colitis
American College of Gastroenterology / EBGI Articles / IBD / Mirikizumab Is Effective for Induction and Maintenance of Ulcerative ColitisMirikizumab Is Effective for Induction and Maintenance of Ulcerative Colitis Rahul Dalal, MD, MPH Instructor, Division of Gastroenterology, Hepatology, and…
-
Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment?
American College of Gastroenterology / EBGI Articles / IBD / Is Early Ileocecal Resection for Crohn’s Disease An Appropriate Primary Treatment?Is Early Ileo-cecal Resection for Crohn’s Disease an Appropriate Primary Treatment? Bharati Kochar, MD, MS Assistant Professor of Medicine,…